Efficacy and tolerance of <scp>GELOXD</scp>/P‐<scp>GEMOXD</scp> in newly diagnosed nasal‐type extranodal <scp>NK</scp>/T‐cell lymphoma: A multicenter retrospective study

Li, Jiwei; Li, Yajun; Zhong, Meizuo; Liu, Xianling; Li, Kunlun; Liu, Xiyu; Zhou, Fang; Ouyang, Zhou; Sun, Zhongyi; Huang, Lijun; He, Jiabei; Zhou, Hui; Yi, Ping

doi:10.1111/ejh.13004

Cited by 25 publications

(25 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our results support previous observations that the baseline SUVmax correlates with prognosis in ENKTCL [35]. The PINK score represents a new model used to predict outcomes in ENKTCL patients treated with non-anthracycline-based therapies, and this model was con rmed in subsequent studies [7,36]. Our research assessed the impact of the PINK on prognosis and found that a high PINK score was associated with a worse outcome.…”

Section: Discussionsupporting

confidence: 89%

“…As lymphoma cells lack L-asparagine synthetase and are unable to synthesize the essential amino acid asparagine, Lasparaginase and Peg can exert anticancer effects by hydrolyzing serum asparagines in ENKTCL patients. Some Lasp/Peg based regimens such as GELOXD, SMILE and DDGP have been developed in the last decade and have been proven to be effective in ENKTCL patients [1,7,23]. In this study, L/P-VIPD resulted in excellent survival outcomes, with 5year PFS and 5-year OS rates of 73.6% and 88.7%, respectively, consistent with the results of a previous study [8].…”

Section: Discussionsupporting

confidence: 88%

See 1 more Smart Citation

Clinical Significance of Circulating Exosomal PD-L1 and Soluble PD-L1 in Nasal-type NK/T-cell Lymphoma Patients Receiving VIPD Containing Chemotherapy

Wei

Guo

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

Background: Several studies showed that circulating exosomal PD-L1 was associated with immunosuppression and prognosis in cancer patients. However, its prognostic value in extranodal NK/T cell lymphoma (ENKTCL) was poorly understood.Methods: We retrospectively evaluated the prognostic value of pretreatment circulating PD-L1+ exosomes and soluble PD-L1 in the plasma of ENKTCL patients treated with VIPD-containing chemotherapy. Results: A total of 107 ENKTCL patients, including 101 early stage and 6 advanced stage patients were enrolled in our study. Most patients were middle-aged and young male adults, with a male to female ratio of approximately 3.7:1. The 5-year progression-free survival (PFS) and 5-year overall survival (OS) rates were 65.2% and 85.7% for the whole cohort, respectively. For early-stage patients, the L/P-VIPD group had better 5-year PFS than the VIPD group (73.6% vs. 53.7%, P=0.031). Compared with the healthy individuals (n=16), the patients with ENKTCL exhibited significantly elevated exoPD-L1 and sPD-L1 levels in the blood. Five-year PFS and OS rates were significantly lower in the high exoPD-L1 and sPD-L1 group than in the low exoPD-L1 and sPD-L1group. However, no correlation was found between circulating exoPD-L1 and sPD-L1 levels (P=0.12, r=0.45).Conclusions: Our results demonstrated that VIPD-containing chemotherapy combined with radiotherapy was a promising regimen in ENKTCL patients. Circulating exoPD-L1 and sPD-L1 levels were significantly elevated in ENKTCL and might be potential biomarkers for predicting the survival outcomes of ENKTCL patients.

show abstract

Section: Discussionsupporting

confidence: 89%

Section: Discussionsupporting

confidence: 88%

Clinical Significance of Circulating Exosomal PD-L1 and Soluble PD-L1 in Nasal-type NK/T-cell Lymphoma Patients Receiving VIPD Containing Chemotherapy

Wei

Guo

et al. 2020

Preprint

Self Cite

View full text Add to dashboard Cite

show abstract

“…We named this new treatment the SVILE regimen. Our control regimen was based on the commonly used PemOx/GELOX 26 , which has a positive effect on ENKTL. PemOx/GELOX treatment consists of pegaspargase, gemcitabine, and oxaliplatin, and is denoted P-GemOx.…”

Section: Discussionmentioning

confidence: 99%

“…Previous studies have reported a CR rate of patients with early ENKTL after GELOX sandwich chemoradiation of 74%, and a total efficacy rate of 96%, values comparable to the results of our study. Li et al 26 , in a retrospective multicenter study, have reported that the CR rate after treatment with gemcitabine, oxaliplatin, L-asparaginase, and dexamethasone (GELOXD)/gemcitabine, oxaliplatin, pegaspargase, and dexamethasone (P-GEMOXD) for patients with ND-ENKTL is 83%. In another retrospective study, the ORR and CR rates of patients with ND-ENKTL in stage I/II after receiving P-GEMOX sandwich chemoradiation have been found to be 94.3% and 80.0%, respectively.…”

Section: Discussionmentioning

confidence: 99%

Outcomes of patients treated with SVILE <i>vs</i>. P-GemOx for extranodal natural killer/T-cell lymphoma, nasal type: a prospective, randomized controlled study

et al. 2020

View full text Add to dashboard Cite

“…Normal cells can avoid death by synthesizing sufficient endogenous asparagine through asparagine synthetase [ 12 ]. Currently, regimens of GELOX (gemcitabine, oxaliplatin, L-asparaginase/pegaspargase) [ 13 ], SMILE (dexamethasone, methotrexate, ifosfamide, L-asparaginase/pegaspargase, etoposide) [ 14 ], VLP (vincristine, L-asparaginase/pegaspargase, prednisone) [ 15 ], VIDL (etoposide, ifosfamide, dexamethasone, L-asparaginase/pegaspargase) [ 16 ], and MIDLE (methotrexate, ifosfamide, dexamethasone, L-asparaginase/pegaspargase, etoposide) [ 17 ] are proven to be effective to treat ENKTL. The treatment modalities of early-stage ENKTL include concurrent, sequential, and “sandwich” chemoradiotherapy.…”

Section: Introductionmentioning

confidence: 99%

Short-Course Versus Long-Course Chemoradiotherapy for Stage IE–IIE Extranodal Natural Killer/T cell Lymphoma, Nasal Type: A Multicenter Retrospective Study

Zhong

et al. 2018

Med Sci Monit

Self Cite

View full text Add to dashboard Cite

BackgroundThis study compared clinical outcomes and adverse events between L-asparaginase/pegaspargase-based short-course and long-course chemoradiotherapy in newly diagnosed stage IE–IIE extranodal natural killer/T cell lymphoma, nasal type (ENKTL).Material/MethodsPatients were categorized into a short-course (2–4 chemotherapy cycles, median: 4, n=153) and long-course group (5–6 cycles, median: 6, n=83). The chemotherapy regimens included GELOX, SMILE, and VLP. The radiotherapy dose was 40–63 Gy (median: 55 Gy). Adverse events, treatment responses, and survival outcomes between the 2 groups were compared.ResultsAnn Arbor stage IIE and short-course chemotherapy adversely affected overall survival (OS). Ann Arbor stage IE favorably affected progression-free survival (PFS). Grade 3–4 hematological toxicities were higher in the long-course group (25.3% vs. 14.4%, p=0.038). Ann Arbor stage was the single different clinical feature between the 2 groups, and independently affected survival outcomes. In subgroup analysis of stage IE, there was no difference in response rates and survival outcomes between the 2 groups. In subgroup analysis of stage IIE, the recurrence and death rates were significantly lower in the long-course group (6.1% vs. 23.2%, p=0.015; 12.2% vs. 39.3%, p=0.002; respectively), and the 3-year OS and PFS rates were much longer in the long-course group (87.8% vs. 62.5%, p<0.001; 83.7% vs. 57.1%, p=0.001; respectively).ConclusionsWhen radiotherapy was combined with L-asparaginase/pegaspargase-based chemotherapy to treat early-stage ENKTL patients, 2–4 cycles of chemotherapy might be sufficient for stage IE patients, while stage IIE patients might require 5+ cycles.

show abstract

Efficacy and tolerance of GELOXD/P‐GEMOXD in newly diagnosed nasal‐type extranodal NK/T‐cell lymphoma: A multicenter retrospective study

Abstract: The GELOXD and P-GEMOXD chemotherapy regimens are well tolerated and provide favorable survival outcomes in patients with ENKTCL.

Cited by 25 publications

References 48 publications

Clinical Significance of Circulating Exosomal PD-L1 and Soluble PD-L1 in Nasal-type NK/T-cell Lymphoma Patients Receiving VIPD Containing Chemotherapy

Clinical Significance of Circulating Exosomal PD-L1 and Soluble PD-L1 in Nasal-type NK/T-cell Lymphoma Patients Receiving VIPD Containing Chemotherapy

Outcomes of patients treated with SVILE <i>vs</i>. P-GemOx for extranodal natural killer/T-cell lymphoma, nasal type: a prospective, randomized controlled study

Short-Course Versus Long-Course Chemoradiotherapy for Stage IE–IIE Extranodal Natural Killer/T cell Lymphoma, Nasal Type: A Multicenter Retrospective Study

Contact Info

Product

Resources

About